P84.15 Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer As First-Line or Sequential Treatment in China

Alectinib is a highly selective inhibitor of anaplastic lymphoma kinase (ALK) with superior systemic and central nervous system (CNS) efficacy. In ALEX study,alectinib yielded confirmed objective response rate(ORR) of 72.4%.The first-time real-world study aims to evaluate the efficacy and safety profile of alectinib in ALK-positive non-small cell lung cancer (NSCLC) Chinese patients.